IFNG and plasma cell myeloma: We have recently developed CS1-CAR-expressing NK-92 cells to target multiple myeloma (MM) cells and demonstrated that these engineered NK-92 cells were able to display enhanced cytolysis and IFN-γ production when co-cultured with MM cells in vitro24.